Physician profile
Scott A Crawshaw
NPI 1306079645
$3,677.31
in general payments reported to CMS, 2019-2025
20 companies · $691 in 2025
The $691 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $229 · 2021: $390 · 2022: $609 · 2023: $726 · 2024: $696 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $637.92 | 2022-2025 | Infuse, Miebo, Biotrue One Day |
| Sun Pharmaceutical Industries INC. | $585.40 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $350.81 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $302.44 | 2021-2025 | Acuvue |
| Coopervision INC. | $252.57 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Novartis Pharmaceuticals Corporation | $237.36 | 2019-2023 | |
| Oyster Point Pharma, INC. | $182.51 | 2022-2023 | Tyrvaya |
| Alcon Vision LLC | $158.33 | 2019-2025 | Total30, Precision7, Precision 1 |
| Amgen INC. | $141.59 | 2025 | Tepezza |
| Lkc Technologies, INC. | $137.05 | 2024 | |
| Allergan, INC. | $132.14 | 2019-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $121.86 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $115.94 | 2024-2025 | |
| Glaukos Corporation | $86.69 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $33.41 | 2025 | Oxervate |
| Abbvie INC. | $23.91 | 2022 | |
| Shire North American Group INC | $20.51 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Kala Pharmaceuticals, INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Crawshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.